In the past 5 years, important advances have been made in the scientific understanding and
clinical management of cholangiocarcinoma (CCA). The cellular immune landscape of CCA …

Background Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as
promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor …

Cholangiocarcinomas (CCA) are a heterogeneous group of tumors that are classified as
intrahepatic, perihilar, or distal according to the anatomic location within the biliary tract …

Purpose: Understanding resistance to selective FGFR inhibitors is crucial to improve the
clinical outcomes of patients with FGFR2-driven malignancies. Experimental Design: We …

Simple Summary Biliary tract cancers (BTCs) are rare tumours associated with poor
prognosis. In advanced-stage disease, two treatment lines are approved: gemcitabine …

Purpose: Genomic rearrangements can generate potent oncogenic drivers or disrupt tumor
suppressor genes. This study examines the landscape of fusions and rearrangements …

Purpose: BRAF mutations are rare in biliary tract cancers (BTC), but are of interest given the
recent developments in targeted therapy for BTC. We investigated the clinical outcomes in a …

Purpose: FGFR2 fusions occur in 10% to 15% of patients with intrahepatic
cholangiocarcinoma (iCCA), potentially benefiting from FGFR inhibitors (FGFRi). We aimed …

ALK, ROS1, and RET fusions and MET∆ ex14 variant associate with response to targeted
therapies in non‐small‐cell lung cancer (NSCLC). Technologies for fusion testing in tissue …

Fibroblast growth factor receptor (FGFR) alterations are present as oncogenic drivers and
bypass mechanisms in many forms of cancer. These alterations can include fusions …